Treatment of Mild to Moderate Depression and Headaches in Adolescents

Initial Management Strategy

The American Academy of Pediatrics recommends beginning with 6-8 weeks of active support and monitoring before initiating formal evidence-based treatment for mild depression, implementing lifestyle interventions including structured physical exercise, sleep hygiene optimization, and adequate nutrition as foundational elements 1, 2, 3
Psychotherapy, specifically cognitive-behavioral therapy (CBT) or interpersonal psychotherapy for adolescents (IPT-A), should be initiated as the primary treatment modality for mild to moderate depression in adolescents, with CBT having an estimated effect size of 1.27 in treating adolescent depression 1, 2, 3

The American Academy of Child and Adolescent Psychiatry recommends fluoxetine as the only FDA-approved antidepressant for children and adolescents with depression, to be considered when psychotherapy alone is insufficient, with a recommended starting dose of 10 mg daily and increase by 10-20 mg increments at no less than weekly intervals 1, 2, 4
Combined fluoxetine plus CBT achieved a 71% response rate versus 35% for placebo, significantly superior to either treatment alone 1, 2

The American Headache Society recommends ibuprofen as first-line medication for headache at a dose appropriate for body weight, with bed-rest alone sufficing for headache attacks of short duration in adolescents 5

Regular in-person assessments are necessary to monitor for suicidal thinking and behavior, with the FDA black box warning emphasizing increased risk of suicidal thinking and behavior in children and adolescents during early antidepressant treatment 1, 2
Common adverse effects include nausea, headaches, behavioral activation, insomnia, asthenia, and somnolence, with higher starting doses of SSRIs associated with increased risk of deliberate self-harm 1, 2

An adequate trial period of 8 weeks at optimal dosage for antidepressants is necessary before concluding treatment is ineffective, with medication maintenance considered for at least 6-12 months after response 1, 2
All SSRIs should be slowly tapered when discontinued to prevent withdrawal effects, with the greatest risk of relapse occurring in the first 8-12 weeks after discontinuation 1, 2

Starting antidepressants at adult doses rather than lower recommended adolescent doses increases the risk of adverse events, and failing to address comorbid conditions, poor adherence, or ongoing environmental stressors will undermine treatment response 1, 3, 6